EXEL data shows far superior to renal cancer drug then the industry leader
good luck all
Summit Research Says CyberArk's Cutting Edge Technology Is Appealing To Many Businesses, Says Cisco And IBM Would Also Have Use For CyberArk Assets, Expects Consolidation In Sector And Believes CyberArk Could Go For A PremiumEddie Staley , Benzinga Staff Writer
CNA Finance 6/24/15 Synergy Pharmaceuticals (SGYP) Stock Climbs Back Up
Moving forward, I’m expecting to see positive news from Synergy Pharmaceuticals in both the short and long term view. Short Term – In the short run, get ready for more big gains, Synergy Pharmaceuticals got plenty of potential for upside growth. Long Term – In the long run, I’m also expecting to see incredibly bullish activity. First off, I’m very impressed with the results of plecanatide thus far; and think that the drug will become even more impressiveafter the release of data from the study that was initiated yesterday.Also, Synergy Pharmaceuticals has demonstrated the fact that they have strong management and a strong core team time and time again
want to be in for that !